Remission Doubled With Risankizumab vs Ustekinumab in CD ...Middle East

Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say. Medscape Medical News

Hence then, the article about remission doubled with risankizumab vs ustekinumab in cd was published today ( Monday 16/10/2023 - 12:12 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Remission Doubled With Risankizumab vs Ustekinumab in CD )

Also on site :

• Employee shot, killed in parking lot of suburban Chicago Amazon facility; lockdown in effect
• Nigel Farage says Reform UK would ‘gladly’ accept more donations from crypto billionaire despite probe
• Amanda Batula Out Of Bravo’s ‘Summer House’ After 9 Seasons